Royalty Pharma (RPRX) EBITDA Margin Growth (1y) (2020 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) EBITDA Margin Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -1,651.00 |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 29,091.00 |
| 10 | Incyte | 25.57 Bn | 21.04 Bn | 1.57 Bn | -194.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,651.00 |
| Mar 31, 2026 | -472.00 |
| Dec 31, 2025 | 154.00 |
| Sep 30, 2025 | -6,007.00 |
| Jun 30, 2025 | -1,393.00 |
| Mar 31, 2025 | 10,699.00 |
| Dec 31, 2024 | -4,193.00 |
| Sep 30, 2024 | 10,194.00 |
| Jun 30, 2024 | 395.00 |
| Mar 31, 2024 | -8,302.00 |
| Dec 31, 2023 | 18,814.00 |
| Sep 30, 2023 | -528.00 |
| Jun 30, 2023 | -2,425.00 |
| Mar 31, 2023 | 3,094.00 |
| Dec 31, 2022 | -11,196.00 |
| Sep 30, 2022 | -1,822.00 |
| Jun 30, 2022 | -6,374.00 |
| Mar 31, 2022 | -92.00 |
| Dec 31, 2021 | -2,824.00 |
| Sep 30, 2021 | -4,310.00 |